Back to Journals » Drug Design, Development and Therapy » Volume 13

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Total article views   HTML views PDF downloads Totals
8,731 Dovepress* 7,829+ 1,230 9,059
PubMed Central* 902 155 1,057
Totals 8,731 1,385 10,116
*Since 24 January 2019

View citations on PubMed Central and Google Scholar